Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$44.48 USD

44.48
281,169

-0.78 (-1.72%)

Updated Aug 30, 2024 03:59 PM ET

After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Zacks Industry Outlook Highlights: 10x Genomics, Omnicell, Inspire Medical Systems and Cerner

Zacks Industry Outlook Highlights: 10x Genomics, Omnicell, Inspire Medical Systems and Cerner

Here's Why You Should Add DexCom (DXCM) Stock to Your Portfolio

Investors continue to be optimistic about DexCom (DXCM) owing to its slew of favorable coverage decisions for its G6 CGM System.

Urmimala Biswas headshot

Buy 3 Medical Info Systems Stocks to Brave Industry-wide Challenges

Stocks like 10x Genomics Inc. (TXG), Omnicell, Inc. (OMCL) and Inspire Medical Systems, Inc. (INSP) are expected to gain despite pandemic-led disruptions.

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.

Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Omnicell (OMCL) Soars 3.4%: Is Further Upside Left in the Stock?

Omnicell (OMCL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

Surmodics' (SRDX) Latest Sublime Catheter Expands Patient Pool

Surmodics' (SRDX) latest addition is expected to aid in performing more complex interventions which were earlier not possible.

Dexcom's (DXCM) G6 CGM System Gets Coverage in Manitoba

Dexcom's (DXCM) CGM System is expected to simplify diabetes management due to increasing access to the life changing technology.

Reasons to Hold on to Inari Medical (NARI) Stock For Now

Investors continue to be optimistic about Inari Medical (NARI) owing to its focus on understanding the venous system and its commitment toward patient care.

Urmimala Biswas headshot

3 Sectors Looking Up Ahead of Q3 Earnings Despite COVID-19 Woes

There has been notable job gains in automotive, hospitality, retail, social assistance and in professional and business services through the past few months.

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.

Here's Why You Should Retain Syneos Health (SYNH) For Now

Investors are optimistic about Syneos Health (SYNH), given the strength in its Clinical Solutions business and notable partnership deals.

3 Reasons Growth Investors Will Love Omnicell (OMCL)

Omnicell (OMCL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

CPSI vs. OMCL: Which Stock Is the Better Value Option?

CPSI vs. OMCL: Which Stock Is the Better Value Option?

Here's Why You Should Add Omnicell (OMCL) to Your Portfolio

Investors continue to be optimistic about Omnicell (OMCL) on its strategic acquisitions and partnerships supporting each of the three legs of its strategy.

Syneos Health's (SYNH) New Buyout Boosts Clinical Solutions Arm

Syneos Health (SYNH) acquisition of StudyKIK strengthens the former's ability to provide technology and insight-driven solutions.

Omnicell (OMCL) New Buyout Expands Patient Engagement Suite

With the FDS Amplicare acquisition, Omnicell (OMCL) is expected to gain from several healthcare trends, banking on its offerings of digital technologies, SaaS solutions, and tech-enabled services.

Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?

Style Box ETF report for SPSM

Is Omnicell (OMCL) a Solid Growth Stock? 3 Reasons to Think " Yes "

Omnicell (OMCL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Urmimala Biswas headshot

3 MedTech Sectors Benefiting Despite COVID-19 Resurgence

Here we discuss three major subsectors of MedTech and some of their constituent stocks for which COVID-19 has opened up enormous growth prospects.

Omnicell (OMCL) Opens New Software Development Center in India

Omnicell's (OMCL) new software development center in Bangalore, India, is expected to bolster the company's cloud-based solutions portfolio.

The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories

The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories